Superworth

SELLAS Life Sciences price to book ratio SLS

Market value divided by the book value of the company's net assets, since 2011.

Today, Nov 2, 2026
12.5×
10-year median
4.4×
Against its 10-year history
86th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.3× to 29.2×
Peer median
2.7×

SELLAS Life Sciences' price to book ratio is 12.5× as of Nov 2, 2026.

That is above its ten-year median of 4.4×, higher than on 86% of days in the last ten years.

Over that time it ranged from 0.3× in Mar 2017 to 29.2× in Aug 2024.

The median for 10 large drugmakers of a similar size is 2.7×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far12.5×10.5×25.9×
20259.0×4.2×16.7×
20244.3×3.9×29.2×
20235.6×2.2×9.8×
20223.9×2.0×17.7×
20213.3×3.3×12.6×
20206.9×1.0×10.0×
20192.0×0.9×6.8×
20181.6×0.4×18.4×
20170.8×0.3×1.0×
20160.9×0.9×32.5×
20157.3×3.7×7.6×
20146.0×5.5×58.5×
201313.0×5.7×13.5×
20127.2×5.2×20.6×
20114.3×3.3×6.2×

Against its peers

Companies in Drug Manufacturers - General nearest SELLAS Life Sciences' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on SELLAS Life Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.